	CD STATES DISTRICT COURT VESTERN DISTRICT OF VIRGINIA ROANOKE DIVISION AT ROANOKE, VA FILED
	APR 2 9 2015
MCAIRLAID'S VLIESSTOFFE	JULIA CADUCULY, CLERK
GMBH, and	BY: DEPUTY CLEST
MCAIRLAIDS, INC.,	3
Plaintiffs,	
v.	Civil Action No. 7/57/208
MEDLINE INDUSTRIES, INC.	3
) TRIAL BY JURY DEMANDED
Defendant.)

COMPLAINT

Plaintiffs McAirlaid's Vliesstoffe GmbH and McAirlaids, Inc. (collectively, "McAirlaids"), by counsel, for its Complaint against Defendant Medline Industries, Inc. ("Medline"), states as follows:

NATURE OF THE ACTION

- 1. This action arises out of Medline's and its dealers', distributors', and resellers' wrongful conduct related to their marketing and sales of Medline's China-made knock-off Ultrasorbs® underpads without McAirlaids' patented SuperCore® technology ("Medline's China-Made Ultrasorbs") which are marketed and sold as counterfeits of the genuine, McAirlaids-produced Ultrasorbs® with McAirlaids' patented SuperCore® technology ("McAirlaids-made, Genuine Ultrasorbs").
- 2. McAirlaids-made, Genuine Ultrasorbs are: (1) made by McAirlaids in the U.S.A. (not in China); (2) marketed and sold as containing an airlaid absorbent core resulting from the process patented in United States Patent No. 6,675,702 (the "'702 Patent") and marketed and sold under McAirlaids' "SuperCore" registered trademark ("Patented SuperCore® Technology"); and (3) marketed and sold with McAirlaids' distinctive and nonfunctional

registered trade dress design consisting of a point pattern of repeating embossed dots ("McAirlaids' Trade Dress").

- 3. Significantly, McAirlaids-made, Genuine Ultrasorbs with McAirlaids' Patented SuperCore® Technology are clinically proven to reduce the incidence of hospital-acquired pressure ulcers, and are marketed and sold to customers, including hospitals and patient-care facilities, based on this proven clinical benefit and corresponding cost-savings with patient care.
- 4. Contrary to Medline's and its dealers', distributors', and resellers' false marketing and advertising, Medline's China-made Ultrasorbs: (1) are not made in the U.S.A.; (2) do not contain McAirlaids' Patented SuperCore® Technology; (3) do not contain McAirlaids' Trade Dress; and (4) are *not* clinically proven to reduce the incidence of hospital-acquired pressure ulcers.
- 5. Despite the fact that Medline's China-made Ultrasorbs are not clinically proven to reduce the incidence of hospital-acquired pressure ulcers and provide the corresponding cost-savings for patient care, Medline and its dealers, distributors, and resellers use false advertising to pass off Medline's China-made Ultrasorbs as McAirlaids-made, Genuine Ultrasorbs with McAirlaids' Patented SuperCore® Technology.
- 6. In so doing, Medline and its dealers, distributors, and resellers defraud customers, including hospitals and patient-care facilities, into falsely believing that Medline's China-made Ultrasorbs provide the same, clinically proven ulcer prevention benefits and corresponding cost-savings with patient care.
- 7. Medline's and its dealers', distributors', and resellers' wrongful conduct presents a grave threat to public health and safety because hospitals, patient-care facilities, and others mistakenly believe that they are purchasing a product which is clinically proven to reduce

pressure ulcers, but instead receive a cheaper-quality, knock-off product with no such proven benefit.

- 8. Medline's and its dealers', distributors', and resellers' wrongful conduct not only presents a grave threat to public health and safety, it presents a grave threat to, and injures McAirlaids' reputation, goodwill in the industry, and economic interests. Because of Medline's and its dealers', distributors', and resellers' false advertising, customers are defrauded into believing that Medline's counterfeit pads are made by McAirlaids in the U.S.A. and contain McAirlaids' Patented SuperCore® Technology and/or Trade Dress.
- 9. After purchasing and receiving the product, however, purchasers discover, contrary to the representations at the time of purchase, that the pads are, in fact, made in China—because this geographic source is printed on the boxes received post-sale—and purchasers discover that the decorative embossed pattern on the purchased product may vary from the advertised McAirlaids' Trade Dress.
- 10. The post-sale disclosure that the pads were made in China would lead purchasers to conclude that McAirlaids is involved in manufacturing cheaper, inferior products in China and that McAirlaids is involved in Medline's and its dealers', distributors', and resellers' false advertising. This post-sale disclosure could also lead purchasers to believe that McAirlaids has adopted a new trade dress pattern and diminish the strength of McAirlaids' Trade Dress.
- 11. Unfortunately for McAirlaids and purchasers, there is no easy way for purchasers to determine, post-sale, that Medline's China-made Ultrasorbs are made without McAirlaids' Patented SuperCore® Technology. Purchasers therefore incorrectly conclude, based on the false advertising at the time of purchase, that Medline's China-made Ultrasorbs contain McAirlaids' Patented SuperCore® Technology and confer the accompanying clinical and cost-saving benefits.

- 12. Purchasers could only discover the inferior quality and performance after using Medline's China-made Ultrasorbs. However, based on Medline's and its dealers', distributors', and resellers' false advertising, purchasers could reasonably (albeit incorrectly) attribute that inferior performance and quality to a reduction in the quality and performance of McAirlaids' Patented SuperCore® Technology. This false advertising and association with inferior performance and quality diminishes the value of McAirlaids' SuperCore® mark and the value of McAirlaids' '702 Patent.
- 13. Medline's and its dealers', distributors', and resellers' wrongful conduct in marketing, advertising and selling Medline's China-made Ultrasorbs have reduced sales of, and demand for, McAirlaids-made, Genuine Ultrasorbs.
- 14. Medline's and its dealers', distributors', and resellers' wrongful conduct are causing immediate, irreparable harm to hospitals, patient-care facilities, and others who mistakenly believe that they are purchasing McAirlaids-made, Genuine Ultrasorbs with Patented SuperCore® Technology that is clinically proven to reduce pressure ulcers, but instead receive a cheaper-quality, knock-off product with no such proven clinical efficacy.
- 15. Medline's and its dealers', distributors', and resellers' wrongful conduct are causing immediate, irreparable harm to McAirlaids' reputation through: (1) McAirlaids' false association with the production of cheaper, inferior products made in China; (2) McAirlaids' association with false advertisements to purchasers; (3) McAirlaids' diminishing goodwill in its SuperCore® mark through its association with Medline's China-made Ultrasorbs; and (4) McAirlaids' diminishing goodwill in its '702 Patent from the patent's association with Medline's China-made Ultrasorbs.
- 16. Medline's and its dealers', distributors', and resellers' wrongful conduct are causing immediate irreparable harm to McAirlaids' economic interest by: (1) reducing sales and

demand for McAirlaids-made, Genuine Ultrasorbs; (2) reducing the goodwill and economic value of McAirlaids' SuperCore® mark and McAirlaids' '702 Patent; (3) intermingling McAirlaids-made, Genuine Ultrasorbs with Medline's China-made Ultrasorbs in the marketplace and creating a false sense of equivalency.

- 17. Based on Medline's and its dealers', distributors', and resellers' wrongful conduct, as alleged herein, Medline is liable to McAirlaids for: (1) trademark infringement, trade dress infringement and counterfeiting under 15 U.S.C. § 1114 (Count I); (2) common law unfair competition (Count II); (3) contributory and/or vicarious infringement arising out of Medline's dealers', distributors' and/or resellers' infringement and counterfeiting of McAirlaids' trademark and trade dress (Count III); (4) false designation of origin under Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a) (Count IV); (5) false advertising under Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a) (Count V); (6) contributory and/or vicarious false advertising and false designation of source and origin arising out of Medline's dealers', distributors' and/or resellers' violations of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125(a) (Count VI); and (7) false advertising under Virginia Code §§ 18.2-216, 59.1-68.3 (Count VII).
- 18. McAirlaids, Inc. has pending claims against Medline in a related case before this Court: McAirlaids, Inc. v. Medline Industries, Inc., Case No. 7:15-cv-6-MFU ("Medline I").
- 19. Due to the exigent need for immediate injunctive relief to prevent continuing irreparable harm to McAirlaids, purchasers, and patients, and the fact that the wrongs alleged herein relate to wrongful conduct arising out of and related to the false advertising and sales of Medline's China-made Ultrasorbs, which are not transactions or occurrences at issue in *Medline I*, McAirlaids is filing this action. McAirlaids, however, intends to move to consolidate this action with *Medline I* and/or amend to consolidate the claims and allegations into one Complaint.

PARTIES

- 20. McAirlaid's Vliesstoffe GmbH ("McAirlaid's GmbH") is a German private limited liability company with its principal place of business in Steinfurt, Germany. McAirlaid's GmbH is the parent company of McAirlaids, Inc.
- McAirlaids, Inc. is a Virginia corporation with its principal place of business in Rocky Mount, Virginia. McAirlaids, Inc. is a wholly owned subsidiary of McAirlaid's GmbH.
- 22. Upon information and belief, Medline is an Illinois corporation with its principal place of business in Mundelein, Illinois. Medline is registered to do business in the Commonwealth of Virginia.

JURISDICTION AND VENUE

- 23. This Court has subject matter jurisdiction over this action under 28 U.S.C. § 1332 as the amount in controversy exceeds Seventy-Five Thousand Dollars (\$75,000.00), exclusive of interest, costs and attorneys' fees, and the matter in controversy is between citizens of different states. This Court also has subject matter jurisdiction pursuant to 15 U.S.C. §§ 1116 and 1121(a) and 28 U.S.C. §§ 1331, and 1338(a) & (b). This Court has supplemental jurisdiction over the state common law claims under 28 U.S.C. § 1367(a).
- 24. This Court has personal jurisdiction over Medline because Medline conducts and has conducted ongoing and continuous business in the Commonwealth of Virginia and the Western District of Virginia, and because Medline is subject to jurisdiction under Virginia Code § 8.01-328.1. By its physical presence in Virginia and this District, Medline has engaged in business dealings and has contracted with persons and entities in Virginia and this District. Medline has purposefully directed its business activities toward Virginia and this District. Through its conduct, Medline has purposefully availed itself of the privileges of conducting

business in Virginia and this District. While engaging in its conduct, it was reasonably foreseeable that Medline would be subjected to this Court's jurisdiction.

25. Venue is appropriate in this Court pursuant to 28 U.S.C. § 1391(b) and (c) in that Medline is subject to personal jurisdiction in this District. Venue in this Court is also appropriate because a substantial part of the events or omissions giving rise to McAirlaids' claims against Medline occurred in the cities or counties constituting the Roanoke Division.

FACTUAL BACKGROUND

26. At all times since 2005, McAirlaids has been in business in the United States manufacturing, selling and/or marketing medical and hygienic absorbent pads, including absorbent incontinence bed pads.

McAirlaids' '702 Patent

- 27. McAirlaids is the owner by assignment from the inventor Alexander Maksimow of the '702 Patent, entitled "Method and Device for Producing a Strip of Cellulose Fiber Material for Use in Hygiene Articles," which was duly and legally issued by the United States Patent and Trademark Office on January 13, 2004. A copy of the '702 Patent is attached hereto as **Exhibit A** and incorporated by reference.
- 28. McAirlaids' '702 Patent gives McAirlaids the exclusive right to use its patented process to create the resulting, highly absorbent airlaid core for use in products throughout the United States.

McAirlaids' SuperCore Trademark

29. McAirlaids owns U.S. Registration No. 2,516,219 for the SuperCore® word mark which was issued on the Principal Register by the United States Patent and Trademark Office on December 11, 2001. A copy of the registration certificate for McAirlaids' SuperCore® is attached hereto as **Exhibit B** and incorporated by reference.

- 30. McAirlaids' SuperCore® federal trademark registration gives McAirlaids the exclusive right to use its mark throughout the United States, and the right to prevent the counterfeit use of its SuperCore® mark.
- 31. McAirlaids SuperCore® registration covers, among other things, "NON-WOVEN FABRICS OF CELLULOSE FIBERS", IN CLASS 24 (U.S. CLS.42 AND 50).
- 32. Consistent with this classification, McAirlaids SuperCore® mark is and has been used in marketing and advertising to identify McAirlaids' highly absorbent, airlaid core produced using McAirlaids' '702 Patented process.
- 33. McAirlaids has made a substantial investment in the promotion and protection of its SuperCore® mark to identify its highly absorbent, airlaid core produced using McAirlaids' '702 Patented process.
- 34. McAirlaids has used the SuperCore mark to market and advertise its highly absorbent, airlaid core produced as a result of McAirlaids' '702 Patented process since at least 1999.
- 35. Indeed on April 27, 1999, prior to being a registered mark, SuperCore™ was used as a source identifier for the now-patented '702 Patented process, and won the prestigious Index '99 Award for advances in the nonwovens. Industry publications, such as "Medical Textiles," published the award stating:

During the opening ceremony of the Index '99 exhibition held in April in Geneva, Switzerland, one of the four awards for advances in nonwovens was presented to McAirlaid's in the category "Nonwoven roll goods for disposable end-uses".

The winning product, called SuperCore, is a pre-manufactured binder- and gluefree absorbent core for hygiene products. The thin nonwoven fabric needs only to be unwound and cut. It is said to feature very fast fluid distribution with super fast absorption, excellent wicking, no gel blocking and no barriers caused by latex, thermal fibres or hot melts.... See Award for SuperCore, Medical Textiles (July 1, 1999) available at http://www.highbeam.com/doc/1G1-55055889.html.

- 36. Since its inception, McAirlaids has continued to use SuperCore ™ and SuperCore® to market, advertise and sell its highly absorbent, airlaid core produced as a result of McAirlaids¹ *702 Patented process
- McAirlaids considers the SuperCore® mark among its most important and valuable assets.
- 38. McAirlaids' SuperCore® mark confers upon McAirlaids the exclusive right to exploit commercially McAirlaids' SuperCore® mark and bar the unauthorized use by third parties of any similar mark that creates a likelihood of confusion.

McAirlaids' Trade Dress

- 39. Since 2005, McAirlaids' absorbent pads have had McAirlaids' Trade Dress.
- 40. McAirlaids owns U.S. Registration No. 4,104,123 for McAirlaids' Trade Dress, which was issued on the Principal Register by the United States Patent and Trademark Office on February 28, 2012. A copy of the registration certificate for McAirlaids' Trade Dress is attached hereto as **Exhibit C** and incorporated by reference. McAirlaids' federal trademark registration gives McAirlaids the exclusive right to use McAirlaids' Trade Dress throughout the United States in connection with absorbent pads.
- Since 2005, McAirlaids has sold over 200 million absorbent pads in the United
 States with McAirlaids' Trade Dress.
- 42. Companies in the absorbent pad industry use their respective trade dress patterns to package their pads in order for purchasers to readily identify one company's pad from the others. To that end, McAirlaids advertises and markets its absorbent pads with McAirlaids' Trade Dress through, among other channels, brochures, trade shows, and the internet, and

directly to customers via an exclusive sales arrangement with Medline. Since 2005, McAirlaids has spent substantial sums in advertising and marketing its absorbent pads with McAirlaids' Trade Dress in the United States. A representative advertisement for McAirlaids' absorbent pads which prominently features and promotes McAirlaids' Trade Dress is attached hereto as **Exhibit D** and incorporated by reference.

43. McAirlaids has developed substantial goodwill in McAirlaids' Trade Dress, which is associated closely with McAirlaids' absorbent pads, including McAirlaids-made, Genuine Ultrasorbs, and McAirlaids' Trade Dress serves to identify and distinguish McAirlaids' absorbent pads from those of others and to indicate the source, origin, sponsorship and affiliation of McAirlaids-made absorbent pads.

Medline's Marketing of McAirlaids' Patented SuperCore® Technology and Trade Dress on McAirlaids-made, Genuine Ultrasorbs

- 44. Since in or around 2006, Medline has marketed, advertised and sold McAirlaids-made, Genuine Ultrasorbs that were manufactured exclusively by McAirlaids using both the Ultrasorbs® mark and the SuperCore® mark, to identify McAirlaids' Patented SuperCore® Technology, to hospitals, clinics, nursing homes, intensive care units, critical care units, emergency rooms, home health-care stores and/or e-commerce purchaser sales.
- 45. A representative sample of Medline's early marketing materials, "the power of one" © 2007, is attached hereto as **Exhibit E** and incorporated by reference. Among other things, this marketing material states:

Supercore® thermo-bonded core does not come apart or bunch up like traditional disposable underpads

Advanced SuperCore® Absorbent Sheet

- thermo-bonded to provide better pad integrity and superior skin dryness
- Advanced thermo-bonded SuperCore® wicks moisture away from the skin and locks fluid away for increased patient dignity and better skin care

- Super absorbent one [Ultrasorbs AP] equals the absorbency of three or more traditional underpads
- High-strength pad and film provide exceptional resistance to tearing and resulting linen changes[1]

©2007 Medline Industries, Inc.


Medline and Ultrasorbs are registered trademarks of

Medline Industries, Inc.

SuperCore is a registered trademark of

McAirlaid's Vliesstoffe GmbH & Co. (emphasis in original).

46. Medline's "the power of one" © 2007 marketing materials, **Exhibit E**, also prominently display McAirlaids' Trade Dress:



¹ High tensile strength is yet another feature of McAirlaids' '702 Patented process which is identified by the SuperCore® mark. See <u>Ex. A</u> at col. 9, ll. 49-50 (claim 1 stating: "A method for producing an absorbent fiber web which is tear resistant . . ."); id. at col. 10, ll. 4-5 ("the tear strength of the fiber web is at least 0.12 kN/m").

- 47. In addition to direct sales through Medline, Medline uses a network of dealers, distributors, and resellers to sell products, including underpads marketed under both the SuperCore® and Ultrasorbs® marks, such as McAirlaids-made, Genuine Ultrasorbs.
- 48. Medline provides its dealers, distributors, and resellers with products for sale to end-users and encourages, induces and/or requires that dealers, distributors, and resellers use Medline's advertising and marketing materials when marketing, advertising and selling the associated products, including underpads marketed under both the SuperCore® and Ultrasorbs® marks, such as McAirlaids-made, Genuine Ultrasorbs.
- 49. Medline also has an apparent or actual partnership with its dealers, distributors, and resellers, and Medline exercises joint ownership or control over the products Medline supplies to its dealers, distributors, and resellers for sale to end-users.
- 50. Indeed, Medline created and provides to its dealers, distributors, and/or resellers a self-described "Marketing Kit" entitled "Qx Quality Customer Solutions For the Home Medical Dealer." A copy of this Marketing Kit is attached hereto as **Exhibit F** and incorporated by reference.
- 51. The Marketing Kit: (1) includes a module-based training program; (2) refers dealers, distributors, and/or resellers to Medline's on-line training curriculum where "staff can receive certification as incontinence care professionals (ICPs)"; and (3) refers dealers, distributors, and/or resellers to Medline's Product Reference Sheets that include underpads marketed under both the SuperCore® and Ultrasorbs® marks, such as McAirlaids-made, Genuine Ultrasorbs.
- 52. The Marketing Kit expressly encourages and induces dealers, distributors, and/or resellers to use Medline's marketing and advertising materials, stating: "Please encourage your

staff to familiarize themselves with these [Product Reference] sheets and use them to help explain products to customers over the phone and in your store." Ex. F at 2.

- 53. The Marketing Kit also supports Medline's and its dealers', distributors', and/or resellers' apparent or actual partnership and joint control over the products. *See*, *e.g.*, Ex. F, Module 2 at 9 ("[E]xplain when the customer can expect to receive their order. (With Medline's dropship program, customers often receive their delivery within 24 to 48 hours'); Ex. F, Module 3, at 8 ("With Medline's on-line training curriculum, [your] staff can receive certification as incontinence care professionals (ICPs)").
- 54. Medline's Marketing Kit is merely one such example of Medline's encouragement, inducement and/or apparent or actual partnership and joint control with respect to the products sold by Medline's dealers, distributors, and/or resellers. On information and belief, Medline's agreements with its dealers, distributors, and/or resellers further support Medline's encouragement, inducement and/or apparent or actual partnership and joint control.
- 55. McAirlaids has never expressly or impliedly authorized Medline or its dealers, distributors, or resellers to use McAirlaids' SuperCore® mark in connection with products that are not manufactured and sold by McAirlaids.
- 56. McAirlaids has never expressly or impliedly authorized Medline or its dealers, distributors, or resellers to use McAirlaids' SuperCore® mark in connection with any products manufactured by Medline or other third-parties for or on behalf of Medline.
- 57. McAirlaids has never expressly or impliedly authorized Medline or its dealers, distributors, or resellers to use McAirlaids' Trade Dress in connection with products that are not manufactured and sold by McAirlaids.

58. McAirlaids has never expressly or impliedly authorized Medline or its dealers, distributors, or resellers to use McAirlaids' Trade Dress in connection with any products manufactured by Medline or other third-parties for or on behalf of Medline.

Medline's Marketing of the Hospital Study & the Proven Clinical & Cost-Saving Benefits of McAirlaids-made, Genuine Ultrasorbs.

- 59. In March 2009, the Global Health Economic Projects, LLC released the results of its hospital study on the efficacy and cost-savings resulting from the use of McAirlaids-made, Genuine Ultrasorbs containing McAirlaids' Patented SuperCore® Technology.
- 60. The hospital study by Shannon, R. and LaJoie, J., entitled Economic Impact of Ultrasorbs AP Absorbent Pads in Prevention of Hospital-Acquired Pressure Ulcers. Global Health Economic Projects, LLC and New York Methodist Hospital, Brooklyn NY. March 2009 ("Hospital Study") is attached hereto as Exhibit G and incorporated by reference.
- 61. Among other things, the Hospital Study found that during the period of the study at New York Methodist Hospital McAirlaids-made, Genuine Ultrasorbs containing McAirlaids' Patented SuperCore® Technology:
 - [W]ere effective in reducing the incidence of hospital-acquired pressure ulcers by an average of 3% in incontinent patients admitted without a pressure sore.
 - The cost savings is estimated at \$96.72 per incontinent patient admitted to the hospital.
 - The annual budget impact is estimated at \$773,760.00 mainly due to the implementation of Ultrasorbs® AP pads.
- 62. With the clinical and cost-savings benefits established, Medline and its dealers, distributors, and/or resellers have relied heavily on this Hospital Study to advertise, market and sell McAirlaids-made, Genuine Ultrasorbs to hospitals, clinics, nursing homes, intensive care units, critical care units, emergency rooms, home health-care stores and/or e-commerce purchasers since March 2009.

- 63. A representative sample of Medline's advertising and marketing materials touting the clinical and cost-savings benefits of McAirlaids-made, Genuine Ultrasorbs with McAirlaids' Patented SuperCore® Technology entitled "advanced technology for patient care Ultrasorbs® Drypads" © 2010, is attached hereto as **Exhibit H** and incorporated by reference. *See also* Ex. F at Ultrasorbs® AP, Ultrasorbs® ES, and Ultrasorbs UF Product Reference Sheets (using the SuperCore® mark and citing the Hospital Study and its clinical and cost saving benefits).
- 64. Exhibit F and Exhibit H market and advertise McAirlaids-made, Genuine Ultrasorbs with McAirlaids' Patented SuperCore® Technology and the clinical and cost-saving benefits stating.
- 65. Exhibit H, for example, markets McAirlaids-made, Genuine Ultrasorbs with McAirlaids' Patented SuperCore® Technology as follows:

Ultrasorbs are cost-effective . Found in 1 in 3 hospitals today. Protects against leakage that leads to multiple lines. and underpad changes. High-strength design reduces the need for multiple drawsheats. for positioning. One Ultrasorbs does the job of up to 4 regular underpads. Ultrasorbs respects individuals Tharmo-bonded SuperCore" pulls moisture away quintily and looks. it away from the skin. Air-permeable, orinkle-free design is quiet, comtentable and discreet. Enhanced odor control feature makes onre more pleasant. Ultrasorbs performs Computible with low-air-loss mattresses used to prevent pressure ulcers. Catheter alternative when indwelling catheter upage is curtailed. due to CAUTI concerns. Clinically shown to help maintain skin integrity as part of an overall pressure ulder prevention program? Ask your Medine sep for a PREE sample of Ultrasorba to fry in your facility? Shannon, R. Lauble, J. Economic Impact of Ultrasorbe* AP Absorbent Pada in Prevention of Hospital Acquired Pressure Ulders, Global Health Economic Projects, LLC and New York Methods Hospital, Brooklyn NY, March 2009.

Medline's False Advertisement, Infringement & Counterfeiting of McAirlaids-made, Genuine Ultrasorbs

- 66. McAirlaids is and has been the exclusive supplier of McAirlaids-made, Genuine Ultrasorbs.
- 67. Unbeknownst to McAirlaids, end-purchasers and end-users, in or around 2014, Medline began surreptitiously manufacturing Medline's China-made Ultrasorbs without McAirlaids' Patented SuperCore® Technology in China, and Medline and its dealers, distributors, and resellers, began marketing and selling Medline's China-made Ultrasorbs as counterfeits of McAirlaids-made, Genuine Ultrasorbs in the United States.
- 68. Unlike McAirlaids-made, Genuine Ultrasorbs which are advertised and sold based on the fact that they (1) are made in the U.S.A., (2) contain McAirlaids' Patented SuperCore® Technology, (3) have proven clinical and cost-saving benefits, and (4) contain McAirlaids' Trade Dress, Medline's China-made Ultrasorbs are counterfeits that are falsely advertised as being identical and indistinguishable from McAirlaids-made, Genuine Ultrasorbs.
- 69. Contrary to Medline's and its dealers', distributors', and resellers' false marketing and advertising, Medline's China-made Ultrasorbs (1) are not made in the U.S.A., (2) do not contain McAirlaids' Patented SuperCore® Technology, and (3) may or may not contain McAirlaids' Trade Dress.
- 70. Moreover, Medline's China-made Ultrasorbs are not clinically proven to "help maintain skin integrity as part of an overall pressure ulcer prevention program," are not proven to provide associated cost-savings, and were not tested under the Hospital Study that is used to market Medline's China-made Ultrasorbs.
- 71. Medline and its dealers', distributors', and resellers' false advertising and infringement of McAirlaids' Patented SuperCore® Technology is particularly pernicious because it jeopardizes patient health and safety. Over the years, many large, end-users, such as hospitals,

clinics, nursing homes, intensive care units, critical care units, and emergency rooms have come to rely on McAirlaids-made, Genuine Ultrasorbs for its clinically proven benefits.

- 72. As a result of Medline and its dealers', distributors', and resellers' false advertising and infringement of McAirlaids' Patented SuperCore® Technology, patients are not being treated with McAirlaids-made, Genuine Ultrasorbs with the clinical efficacy and cost-savings benefits proven in the advertised Hospital Study.
- 73. On information and belief, even though Medline's China-made Ultrasorbs are cheaper to manufacture and produce and are inferior in quality and performance, Medline and its dealers, distributors, and resellers are selling Medline's China-made Ultrasorbs at or around the same price as McAirlaids-made, Genuine Ultrasorbs to avoid tipping end-users off to its counterfeit and to reap even greater ill-gotten profits at the cost of patient health and safety.
- 74. Prior to April 16, 2015, McAirlaids was unaware of the fact that Medline was manufacturing China-made Ultrasorbs.
- 75. In a Memorandum in Support of a Motion to Strike file by counsel for Medline in *Medline I*, Medline's counsel stated that "Medline started sourcing Ultrasorbs® AP pads from a supplier other than McAirlaids." *Medline I* (Dkt. # 24) at 2, n.1.
- 76. Medline also stated to McAirlaids that it was reducing its purchases of McAirlaids-made, Genuine Ultrasorbs from McAirlaids, and has, in fact, reduced its purchases of McAirlaids-made, Genuine Ultrasorbs.
- 77. Upon further investigation, McAirlaids has discovered direct evidence that Medline and its dealers, distributors, and resellers have been actively engaged in a false advertising campaign and passing-off Medline's China-made Ultrasorbs as McAirlaids-made, Genuine Ultrasorbs.

- 78. McAirlaids has never expressly or impliedly authorized Medline or its dealers, distributors or resellers to use the SuperCore® mark in connection with Medline's China-made Ultrasorbs.
- 79. McAirlaids has never expressly or impliedly authorized Medline or its dealers, distributors or resellers to reference or use McAirlaids' '702 Patented process in connection with Medline's China-made Ultrasorbs.
- 80. McAirlaids has never expressly or impliedly authorized Medline or its dealers, distributors, and resellers to use McAirlaids' Trade Dress in connection with Medline's Chinamade Ultrasorbs.

Direct Evidence of Medline's False Advertising, False Designation of Source and Origin, Infringement & Counterfeiting of McAirlaids-made, Genuine Ultrasorbs

Medline's Website

- 81. Medline's website currently markets and passes-off Medline's China-made Ultrasorbs as McAirlaids-made, Genuine Ultrasorbs.
- 82. Although Medline currently sells its China-made Ultrasorbs along with McAirlaids-made, Genuine Ultrasorbs, Medline's website and marketing materials do not distinguish Medline's China-made Ultrasorbs from McAirlaids-made, Genuine Ultrasorbs. Rather, the marketing and advertising materials are intended to and do falsely represent and pass off Medline's China-made Ultrasorbs as McAirlaids-made, Genuine Ultrasorbs.
- 83. Indeed, Medline's "Incontinence Care" page, © 2015, advertises Medline's China-made Ultrasorbs as "made in the U.S.A." and "Clinically Proven to Reduce Pressure Ulcers." https://www.medline.com/products/incontinence-care/ (last accessed April 29, 2015). A copy of Medline's "Incontinence Care" page is attached hereto as Exhibit I and incorporated by reference.

- 84. In Exhibit I, Medline falsely represents the geographic source of Medline's China-made Ultrasorbs as "made in the U.S.A."
- 85. In Exhibit I, Medline also falsely represents that it (rather than McAirlaids) is the source and origin of SuperCore®. At the bottom of the "Incontinence Care" page, Medline states that "Aloetouch, FitRight, Protection Plus, Restore, SuperCore, and Ultrasorbs are registered trademarks and Capri Plus is a trademark of Medline Industries." (emphasis added). Significantly, Aloetouch®, FitRight®, Protection Plus®, Restore®, Ultrasorbs® and Capri Plus®, are all registered trademarks of Medline. By including SuperCore® among the list of Medline registered trademarks, with no attribution to McAirlaids, Medline is misrepresenting the source and origin of SuperCore® and McAirlaids' Patented SuperCore® Technology.
- 86. After falsely representing that Medline's China-made Ultrasorbs are "Clinically Proven to Reduce Pressure Ulcers," Medline's "Incontinence Care" page, **Exhibit I**, has a "Learn More" link directing the user to Medline's Ultrasorbs® Underpads page, © 2015. https://www.medline.com/products/incontinence-care/ultrasorbs-drypads/ (last accessed April 29, 2015). A copy of Medline's Ultrasorbs® Underpads page is attached hereto as **Exhibit J** and incorporated by reference.
- 87. Exhibit J further falsely represents that Medline's China-made Ultrasorbs, which are currently being sold, contain the "Patented SuperCore®" manufactured under McAirlaids' '702 Patent:

Ultrasorbs AP® (Air-Permeable)
The original premium drypad



- Patented SuperCore® absorbent draws in moisture, looks it away from the skin and feets dry to the touch in just minutes.*
- Lies fist when wet thenks to SuperCore® technology, without bunching, swelling or disintegrating.
- AquaShield film provides leakage protection that means fewer lines changes—no doublepadding.
- Air permeable for added comfort, dryness end no emberrassing plastic film crinking.
- Effective for use with low-sir-loss mattress therapy—protects the bedding and permits sirflow.

Ultrasorbs® UF (Ultra-Fresh) Premium odor control drypad



- Antimicrobial Litra-Fresh^{***} protection**
 inhibits the growth of pacteria and yeasts that
 can cause office.
- Locks odor-causing moisture away in the SuperCoreS layer.
- · Makes for a fresher room.
- All the absorbency and dry comfort features of the original Ultresorbs AP.


Ultrasorbs® ES (Extra-Strength)
Premium drypad & drawpad



- Lets you move, lift and position up to 375pounds.
- Innovative Lift Support backsheet technology resists tearing.
- Eliminates the need and expense of extra draw sheets and reusable underpeda for most patients.
- All the absorbency and dry comfort features of the original Ultrasorbs AP.




- 88. Moreover, Exhibit J contains no attribution to McAirlaids, either in connection with SuperCore® or McAirlaids' '702 Patent cited therein, and further supports Medline's false designation of source and origin for SuperCore®.
- 89. Each of the product pictures listed above on Medline's Ultrasorbs® Underpads page, <u>Exhibit J</u>, link to product detail and specification pages. A copy of each of Medline's Ultrasorbs® AP, UF, ES and US product detail pages is attached hereto as <u>Exhibit K</u> and incorporated by reference.
- 90. As with Medline's other advertising and marketing materials used in connection with Medline's China-made Ultrasorbs, these pages falsely pass off Medline's China-made Ultrasorbs as McAirlaids-made, Genuine Ultrasorbs. See, e.g.,:





Material	Desarytion	Parkaging
ULTRABULK2436	UNDERPAD, DRYPAD, ULTRASCRES AP, 24/38*	70/CS
ULTRABULK3136	UNDERPAD, DRYPAD, ULTRASORBS-AP, 31X36"	40/CS
ULTRASORB1016	UNDERPAD, DRYPAD, ULTRASORBS-AP, 10X16"	100/CS
ULTRASORB1824	UNDERPAD, DRYPAD, ULTRASORBS-AP, 18/04*	60°CS
JLTRASORE2436	UNDERPAD, DRYPAD, ULTRASCRIBS AP. 24X36"	7903
JLTRASORB3136	UNDERPAD, DRYPAD, ULTRASORES AP, 31X36"	40/CS
JLTRASRB2436R	UNDERPAD, DRYPAD, JUTRASORBS AP, 24X38	39/CS
JLTRASRB2436Z	UNDERPAD, DRYPAD, ULTRASORIIS AP. 24/08*	10/93
JLTRASRED136Z	UNDERPAD, DRYPAD, ULTRASORBS AP, 31X36"	19/93
JLTRSRB2436LB	UNDERPAD, DRYPAD, ULTRASORB AP, 24X36, 1455	70/CS
ULTRERB3136LB	UNDERPAD DRYPAD, ULTRASORBS AP, 31X35"	40/C3




Ultrasorbs Ultra Fresh Odor Control Drypads



Ordering Information

Malerial	Description	Packaging
USAP2436UF	UNDERPAD, ULTRASORBS WIULTRAFRESH, 24/38*	70/CS
USAP2436UFBLK	UNDERPAD, ULTRASORBS WIUF, 24"X26", BULK	70/CS
USAP3136UF	UNDERPAD, ULTRASORBS WIULTRAFRESH, 31X36"	40/CS







91. The above product detail pages also contain videos and/or images of McAirlaids-made, Genuine Ultrasorbs and allow the user to zoom into each picture to view McAirlaids' prominently displayed Trade Dress.

92. Medline uses all of the above webpages in furtherance of its counterfeiting of McAirlaids-made, Genuine Ultrasorbs.


Purchases from Medline Confirm Infringement, Counterfeiting, False Advertising & False Designation of Origin

Medline's China-made Ultrasorbs Purchase 1

- 93. On April 23, 2015, McAirlaids purchased "Medline Ultrasorbs AP Underpads, White, 24 Inch x 36 Inch, 10 Count (Pack of 7) by Medline" from Medline via Amazon.com with fulfillment by Amazon.com on behalf of Medline ("Medline's China-made Ultrasorbs Purchase 1").
- 94. Medline is responsible for the advertising and marketing material, product description, and product details associated with Medline's China-made Ultrasorbs Purchase 1 on Amazon.com.
- 95. The "Product Description" and "Product Details" for Medline's China-made Ultrasorbs Purchase 1 advertised McAirlaids-made, Genuine Ultrasorbs for sale, not Medline's China-made Ultrasorbs.
- 96. At the time of purchase, the "Product Description" and "Product Details" were as follows:

Product Description

Experience the confidence that an Ultrasorbs AP underpad can provide! Our vision is to improve dignity and overall quality of life for those with incontinence. Unlike some underpads that only protect the furniture, Ultrasorbs AP was designed to lock away moisture fast so it helps keep skin drier.



INSTANTLY LOCKS AWAY WETNESS

What is the value of a good night's sleep? Ultrasorbs uses high absorbent technology to draw moisture away from the skin. And - it does this with a thin comfortable sheet. Ultrasorbs manages moisture over time so you can get a good night's sleep.

TRUSTED BY PROFESSIONALS

Ultrasorbs have been a trusted part of patient care for years.

HIGH PERFORMACE = COST EFFECTIVE

Using Ultrasorbs help protects against leakage that leads to multiple linen and underpad changes, In fact, one Ultrasorbs does the job of up to 4 regular underpads.

COMFORTABLE AND DISCREET

Ultrasorbs respects individuals. Ultrasorbs' has an air-permeable, crinkle-free design that is quiet, comfortable and discreet.



Try Ultrasorbs and experience the Ultrasorbs difference for yourself.

Features

- Super absorbent core technology draws in moisture, locks it away from the skin, and feels dry to the touch in just minutes
- Micro-pore film provides leakage protection that mean fewer linen changes; no double-padding needed
- Lies flat when wet thanks to advanced core technology, and does not bunch, swell, or disintegrate when wet
- · Air-permeable for skin health and added



Product Details

Product Dimensions: 3.8 x 3.8 x 3.8 inches : 2.4 pounds

Shipping Weight: 13.6 pounds (View shipping rates and policies)

Shipping: This item is also available for shipping to select countries outside the U.S.

Shipping Advisory: This item must be shipped separately from other items in your order. Additional shipping charges will not apply.

ASIN: BOOIZUJSPK

Average Customer Review:

(2 customer reviews)

Amazon Best Sellers Rank: #245.147 in Health & Personal Care (See Top 100 in Health & Personal Care)

Would you like to give feedback on images or tell us about a lower price?

97. As shown above, the product was advertised for sale as McAirlaids-made, Genuine Ultrasorbs, not Medline's China-made Ultrasorbs. Consistent only with McAirlaidsmade, Genuine Ultrasorbs, the advertising states that the product contains "Advanced Thermo-Bonded SuperCore[®]," that SuperCore is a "Super absorbent core technology [that] draws in moisture, lock it away from the skin, and feels dry to the touch in just minutes," and "Lies flat when wet thanks to advanced core technology." The advertisement further represents that the product has been a "trusted part of patient care for years" (referring to McAirlaids-made, Genuine Ultrasorbs) and identifies the product "Origin" as "USA," not China. Moreover, the

advertisement uses a product picture of McAirlaids-made, Genuine Ultrasorbs with McAirlaids'
Trade Dress.

- 98. After ordering the advertised McAirlaids-made, Genuine Ultrasorbs with the above representations, McAirlaids did not receive the advertised product. Instead, McAirlaids received Medline's China-made Ultrasorbs confirming Medline's infringing use of SuperCore®, false advertising, counterfeiting and false designation of source and origin.
- 99. The transaction history associated with Medline's China-made Ultrasorbs


 Purchase 1 and pictures of the product received through this purchase, are attached hereto as

 Exhibit L and incorporated by reference.
- 100. The following pictures in <u>Exhibit L</u> demonstrate that Medline's China-made Ultrasorbs were sent directly from Medline to Amazon on or before December 11, 2014.



- 101. The SKU "Ultrasorbs2436," is the same SKU used to identify McAirlaids-made, Genuine Ultrasorbs with Patented SuperCore® Technology and McAirlaids' Trade Dress.
 - 102. The use of identical SKUs further contributes to purchaser confusion.

103. The lot number EW20141017-146 confirms, upon information and belief, that these China-made Ultrasorbs were manufactured on October 17, 2014:



104. The product received with Medline's China-made Ultrasorbs Purchase 1 is also conspicuously marked as "Made in China," confirming Medline's false designation of geographic origin:



105. This false designation of geographic origin is not only a violation of Section 43(a) of the Lanham Act, it is a violation of Section 5 of the Federal Trade Commission Act, 15 U.S.C. § 45, and a violation of Amazon's General Listing Restrictions, available at http://www.amazon.com/gp/help/customer/display.html/ref=hp_rel_topic?ie=UTF8&nodeId=20 1737330:

General Listing Restrictions

Category Restriction

Made in the U.S.A. Any product that you describe, advertise or label as "Made in the U.S.A." must be all or virtually all made in the United States. For more information, see the Federal Trade Commission's Enforcement Policy Statement on U.S. Origin Claims and Advertising and Marketing on the Internet: Rules of the Road. See also the discussions of "Animal Furs and Skins," "Textile Descriptions," and "Wool Product Descriptions" on Listing Restrictions That Require Statements or Disclosures for more information on required disclosures of country of origin.

- 106. By using McAirlaids-made, Genuine Ultrasorbs marketing materials to pass off Medline's China-made Ultrasorbs, Medline is engaged in counterfeiting through the use of identical, indistinguishable advertisements.
- 107. The product received from Medline's China-made Ultrasorbs Purchase 1 and McAirlaids-made, Genuine Ultrasorbs are displayed, side-by side below:

Medline's China-made Ultrasorbs

McAirlaids-made, Genuine Ultrasorbs



Medline's China-made Ultrasorbs

McAirlaids-made, Genuine Ultrasorbs



Medline's China-made Ultrasorbs

McAirlaids-made, Genuine Ultrasorbs



- 108. After receiving Medline's China-made Ultrasorbs, a purchaser would discover that the product was made in China, rather than the U.S.A., and that the embossed pattern varies. Otherwise, McAirlaids-made, Genuine Ultrasorbs and Medline's China-made Ultrasorbs are indistinguishable in appearance, size, weight and feel. The purchaser could only conclude, based on the false advertising, that both contain McAirlaids' Patented SuperCore® Technology.
- 109. Even though the embossed pattern varies, and the geographic origin is not as advertised, the purchaser could reasonably conclude that McAirlaids' has adopted a new trade dress pattern and, like so many other U.S. manufacturers, has started to manufacture products overseas.

110. If and when purchasers discover that the China-made Ultrasorbs are inferior in quality and performance, purchasers would reasonably, but falsely, attribute that poor performance to a diminishment in the quality and performance of McAirlaids' Patented SuperCore® Technology based on Medline's false advertising.

Direct Evidence of Medline's Dealers, Distributors and/or Resellers' False Advertising, Infringement & Counterfeiting of McAirlaids-made, Genuine Ultrasorbs

Medline's China-made Ultrasorbs Purchase 2

- 111. On April 20, 2015, McAirlaids purchased "Medline Ultrasorbs AP Premium Disposable DryPad Ultrasorbs AP, 24" x 36" Qty of 70" from Medline dealer, distributor or reseller VetmedUSA via Amazon.com with fulfillment by VetmedUSA on behalf of Medline ("Medline's China-made Ultrasorbs Purchase 2").
- 112. Medline is responsible for its dealers', distributors' and resellers' marketing material, product description, product features, and product details associated with Medline's China-made Ultrasorbs Purchase 2 on Amazon.com.
- 113. The "Product Description" for Medline's China-made Ultrasorbs Purchase 2 advertised McAirlaids-made, Genuine Ultrasorbs for sale, not Medline's China-made Ultrasorbs.

 At the time of purchase, the "Product Description" was as follows:

Product Description

Ultrasorbs AP are clinically shown to help maintain skin integrity as part of an overall pressure ulcer prevention program1 Extra-large patented2, SuperCore draws in moisture, locksit away from the skin and feels dry to the touchin just minutes AquaShield film provides leakage protection that mean fewer linen changes; no double-padding needed Lies flat when wet thanks to SuperCore technology, without

114. At the time of purchase, VetmedUSA used the following image, prominently displaying McAirlaids' Trade Dress to advertise the sale of Medline's China-made Ultrasorbs Purchase 2:



- 115. As shown above, the product was advertised for sale as McAirlaids-made, Genuine Ultrasorbs, not Medline's China-made Ultrasorbs. Consistent only with McAirlaids-made, Genuine Ultrasorbs, the advertising states that "Ultrasorbs AP are clinically shown to help maintain skin integrity as part of an overall pressure ulcer prevention program1[.] Extra-large patented2, SuperCore[®] draws in moisture, locksit[sic] away from the skin and feels dry to the touchin[sic] just minutes . . . Lies flat when wet thanks to SuperCore[®] technology."
- 116. It is clear that the advertising for Medline's China-made Ultrasorbs Purchase 2 was copied and pasted directly from Medline's marketing materials and product description from Medline's "Ultrasorbs AP Underpads" webpage. Indeed, this product description even contains the same grammatical errors ("touchin[sic]" and "locksit[sic]"). Compare Complaint, ¶¶ 113 and 90. The only difference is the removal of the superscript with footnotes 1 and 2 which is a mere formatting change from copying and pasting the text.
- 117. After ordering the advertised McAirlaids-made, Genuine Ultrasorbs with the above representations, McAirlaids did not receive the advertised product. Instead, McAirlaids received Medline's China-made Ultrasorbs confirming Medline's and its dealer's, distributor's

or reseller's infringing use of SuperCore®, false advertising, counterfeiting and false designation of source and origin.

- 118. The advertisement and transaction history associated with Medline's China-made Ultrasorbs Purchase 2 and pictures of the product received through this purchase, are attached hereto as **Exhibit M** and incorporated by reference.
- 119. By using McAirlaids-made, Genuine Ultrasorbs marketing materials to pass off Medline's China-made Ultrasorbs, Medline and its dealer, distributor and reseller are engaged in counterfeiting through the use of identical, indistinguishable advertisements.
- 120. The product received from Medline's China-made Ultrasorbs Purchase 2 is identical to the product received from Medline's China-made Ultrasorbs Purchase 1.
- that the product was made in China and the embossed pattern varies from the prominently advertised McAirlaids' Trade Dress. Otherwise, McAirlaids-made, Genuine Ultrasorbs and Medline's China-made Ultrasorbs are indistinguishable in appearance, size, weight and feel. The purchaser could only conclude, based on the false advertising, that both contain McAirlaids' Patented SuperCore® Technology, and falsely concluded that it is clinically shown to help maintain skin integrity as part of an overall pressure ulcer prevention program.
- 122. Even though the embossed pattern varies, the purchaser could reasonably conclude that McAirlaids' has adopted a new trade dress pattern and, like so many other U.S. manufacturers, has started to manufacture products overseas.
- 123. If and when purchasers discover that the China-made Ultrasorbs are inferior in quality and performance, purchasers would reasonably, but falsely, attribute that poor performance to a diminishment in the quality and performance of McAirlaids' Patented

SuperCore® Technology based on Medline's and its dealers', distributors' or resellers' false advertising (which derives from Medline's false advertising).

Medline's China-made Ultrasorbs Purchase 3

- 124. On April 20, 2015, McAirlaids also purchased "Medline USAP3136ES Ultrasorbs Extra Strength Drypad & Drawpad, White (Case of 40)" from Medline dealer, distributor or reseller AllDayMedical via Amazon.com with fulfillment by AllDayMedical on behalf of Medline ("Medline's China-made Ultrasorbs Purchase 3").
- 125. On McAirlaids' Packing List for Medline's China-made Ultrasorbs Purchase 3, "All Day Medical" is identified as an "(Internet Account)." Based on the address for "All Day Medical" shown thereon, it appears that AllDayMedical is owned by the Synergy® HomeCare franchise.
- 126. Medline is responsible for its dealers', distributors' and resellers' marketing material, product description, product features, and product details associated with Medline's China-made Ultrasorbs Purchase 3 on Amazon.com.
- 127. The "Product Description" for Medline's China-made Ultrasorbs Purchase 3 advertised McAirlaids-made, Genuine Ultrasorbs for sale, not Medline's China-made Ultrasorbs. At the time of purchase, the "Product Description" was as follows:

Product Description

Help eliminate the need and expense of extra draw sheets and reusable underpads for most patients with this extra strength drypad and drawpad.

- Ultrasorbs ES let you move, lift and position up to 375 pounds.
- Innovative LiftSupport backsheet technology resists tearing.
 All the absorbency and dry comfort features of the original Ultrasorbs AP.
- . Indications: Use Ultrasorbs ES for the same cases as Ultrasorbs AP, plus when repositioning a patient is a concern.
- . USAP3136ESLP has an extra low profile.
- Patents Pending.
- 128. At the time of purchase, AllDayMedical used the following image, prominently displaying McAirlaids' Trade Dress to advertise for sale Medline's China-made Ultrasorbs Purchase 3:



- 129. As shown above, the product was advertised for sale as McAirlaids-made, Genuine Ultrasorbs, not Medline's China-made Ultrasorbs. Consistent only with McAirlaids-made, Genuine Ultrasorbs, the advertising states that it has "All the absorbency and dry comfort features of the original Ultrasorbs AP," which was made only by McAirlaids, and prominently displays McAirlaids-made, Genuine Ultrasorbs in the product image.
- 130. The advertising for Medline's China-made Ultrasorbs Purchase 3 came directly from Medline's marketing materials.
- 131. After ordering the advertised McAirlaids-made, Genuine Ultrasorbs with the above representations, McAirlaids did not receive the advertised product. Instead, McAirlaids received Medline's China-made Ultrasorbs confirming Medline's and its dealer's, distributor's or reseller's infringing use of SuperCore®, false advertising, counterfeiting and false designation of source and origin.

- 132. The advertisement and transaction history associated with Medline's China-made Ultrasorbs Purchase 3 and pictures of the product received through this purchase, are attached hereto as **Exhibit N** and incorporated by reference.
- 133. By using McAirlaids-made, Genuine Ultrasorbs marketing materials to pass off Medline's China-made Ultrasorbs, Medline and its dealer, distributor and reseller are engaged in counterfeiting through the use of identical, indistinguishable advertisements.
- 134. The product received from Medline's China-made Ultrasorbs Purchase 3 is identical in appearance to McAirlaids-made, Genuine Ultrasorbs ES except for the embossed pattern, which is identical to the pattern in products received from Medline's China-made Ultrasorbs Purchases 1 and 2, and the embossed pattern varies from the prominently displayed McAirlaids' Trade Dress advertised.
- 135. Even though the embossed pattern varies, the purchaser could reasonably conclude that McAirlaids' has adopted a new trade dress pattern and has, like so many other U.S. manufacturers, started to manufacture products overseas.
- 136. If and when purchasers discover that the China-made Ultrasorbs are inferior in quality and performance, purchasers would reasonably, but falsely, attribute that poor performance to a diminishment in the quality and performance of McAirlaids' Patented SuperCore® Technology based on Medline's and its dealer's, distributor's or reseller's false advertising (which derives from Medline's false advertising).

Medline Exacerbates Confusion By Using Identical Advertising & Intermingling Inferior China-Made Ultrasorbs & McAirlaids-made, Genuine Ultrasorbs in Order Fulfillment

137. Significantly, Medline and its dealers, distributors and resellers are still selling and marketing McAirlaids-made, Genuine Ultrasorbs.

- 138. The three purchases described herein represent an extremely small sampling of the marketplace. Even using an online marketplace such as Amazon.com, a search for "Ultrasorbs pads" returns 246 results, and for any given product there are often numerous sellers.
- 139. On information and belief, all or nearly all of the advertisements for Ultrasorbs are copied from or derive directly from Medline's marketing materials for McAirlaids-made, Genuine Ultrasorbs.
- 140. Unfortunately for purchasers, Medline and its dealers, distributors and resellers are and have been fulfilling orders received based on advertisements of McAirlaids-made, Genuine Ultrasorbs with either McAirlaids-made, Genuine Ultrasorbs with Patented SuperCore® Technology or Medline's China-made Ultrasorbs without Patented SuperCore® Technology throughout the marketplace.
- Medline's and/or its dealers, distributors and resellers intermingling of inferior Medline's China-made Ultrasorbs which are *not* clinically proven to reduce the incidence of ulcers and provide accompanying cost-saving benefits and do not contain McAirlaids' Patented SuperCore® Technology, with McAirlaids-made, Genuine Ultrasorbs, which *are* clinically proven to reduce the incidence of ulcers and provide accompanying cost-saving benefits and *do* contain McAirlaids' Patented SuperCore® Technology and Trade Dress, is causing actual confusion, a likelihood of confusion and damage to McAirlaids and the goodwill in its SuperCore® mark, its '702 Patented process, and McAirlaids' Trade Dress.
- 142. McAirlaids has been damaged as a consequence of Medline's and its dealers', distributors', and resellers' false advertising, false designation of source and origin, infringement and counterfeiting of McAirlaids' Patented SuperCore® Technology and McAirlaids' Trade Dress. Medline's and its dealers', distributors', and resellers' wrongful conduct, as alleged herein, will cause McAirlaids further immediate and irreparable injury, loss and damage for

which McAirlaids will have no adequate remedy at law, and Medline and its dealers, distributors, and resellers should be preliminarily and permanently enjoined from engaging in such wrongful conduct. Medline's and its dealers', distributors', and resellers' false advertising, false designation of source and origin, infringement and counterfeiting of McAirlaids' Patented SuperCore® Technology and McAirlaids' Trade Dress, show willful misconduct, malice, fraud, wantonness, oppression, or an entire lack of care which would raise the presumption of conscious indifference to its consequences.

COUNT I

(Trademark and Trade Dress Infringement and Counterfeiting Under 15 U.S.C. § 1114)

- 143. McAirlaids repeats and specifically incorporates the allegations asserted in each of the preceding paragraphs, as if fully set forth herein.
- 144. McAirlaids owns U.S. Registration No. 2,516,219 for McAirlaids' SuperCore® word mark. McAirlaids has used and continues to use SuperCore® in connection with its specified goods and/or services in interstate commerce.
- 145. McAirlaids' SuperCore® mark, as registered, is nonfunctional, inherently distinctive or has acquired secondary meaning and is associated in the mind of the public uniquely with McAirlaids and has been and will continue to be known throughout the United States as identifying and distinguishing McAirlaids' goods and/or services.
- 146. McAirlaids owns U.S. Registration No. 4,104,123 for McAirlaids' Trade Dress, and McAirlaids has used and continues to use its Trade Dress in connection with its specified goods and/or services in interstate commerce.
- 147. McAirlaids' Trade Dress, as registered, is nonfunctional, inherently distinctive or has acquired secondary meaning and is associated in the mind of the public uniquely with McAirlaids. McAirlaids' Trade Dress has been and will continue to be known throughout the United States as identifying and distinguishing McAirlaids' goods and/or services.

- 148. Without authorization, Medline has used and continues to use exact copies of McAirlaids' SuperCore® mark and Trade Dress in commerce, in connection with the sale, offering for sale, distribution, or advertising of Medline's China-made Ultrasorbs in a manner that is likely to cause confusion, or to cause mistake, or to deceive, and in a manner that is intended to cause confusion, or to cause mistake, or to deceive.
- 149. Medline's importing, distributing, selling and marketing of its China-made Ultrasorbs in connection with McAirlaids' SuperCore® mark and Trade Dress infringes McAirlaids' exclusive rights in and to McAirlaids' SuperCore® mark and Trade Dress in violation of Section 32 of the Lanham Act, 15 U.S.C. § 1114.
- 150. Medline's use of the SuperCore® mark and Trade Dress in connection with the sale, offering for sale, distribution, or advertising of Medline's China-made Ultrasorbs misleads, confuses and/or deceives consumers into believing they are purchasing McAirlaids-made, Genuine Ultrasorbs that (1) are made by McAirlaids; (2) are made in the U.S.A., (3) contain McAirlaids' Patented SuperCore® Technology, (4) have proven clinical and cost-saving benefits, and (5) contain McAirlaids' Trade Dress. Instead, purchasers receive Medline's China-made Ultrasorbs that (1) are not made by McAirlaids; (2) are not made in the U.S.A., (3) do not contain McAirlaids' Patented SuperCore® Technology, (4) are not proven to have the clinical and cost-saving benefits of McAirlaids-made, Genuine Ultrasorbs, and (5) may or may not contain McAirlaids' Trade Dress.
- 151. Medline has unlawfully used McAirlaids-made, Genuine Ultrasorbs advertising and McAirlaids' SuperCore® mark and Trade Dress to pass off, falsely promote and create a market for Medline's China-made Ultrasorbs and reduce sales of McAirlaids-made, Genuine Ultrasorbs.

- 152. Medline's unauthorized use, adoption, appropriation and/or copying of McAirlaids' SuperCore® mark and Trade Dress deprives McAirlaids of its exclusive rights to control, and benefit from, McAirlaids' SuperCore® mark and Trade Dress.
- 153. If permitted to continue, Medline's actions will nullify McAirlaids' rights to the exclusive use of McAirlaids' SuperCore® mark and Trade Dress, free from infringement, and will have a substantial and adverse effect on McAirlaids' existing and projected future interstate business of marketing and selling its absorbent pads bearing McAirlaids' SuperCore® mark and Trade Dress in violation of 15 U.S.C. § 1114.
- 154. Medline's unauthorized use of McAirlaids' SuperCore® mark and Trade Dress has resulted in Medline unfairly benefiting from advertising and promotion of McAirlaids' SuperCore® mark and Trade Dress and from the resultant goodwill in McAirlaids' SuperCore® mark and Trade Dress.
- 155. By reason of and as a direct and proximate result of Medline's trademark and trade dress infringement, Medline has caused damage to McAirlaids' business, reputation and goodwill and has diverted business and sales from McAirlaids to Medline.
- 156. McAirlaids is entitled to an accounting and to recover from Medline all damages, without limitation, that McAirlaids has suffered due to Medline's infringing conduct, including Medline's profits and damages suffered by McAirlaids in an amount to be proven at trial, the costs of the action, treble damages under 15 U.S.C. § 1117(a), treble damages and reasonable attorneys' fees for Medline's use of the counterfeit SuperCore® mark and counterfeit Trade Dress under 15 U.S.C. § 1117(b), and/or statutory damages for use of the counterfeit mark and/or Trade Dress in lieu of damages and profits under 15 U.S.C. § 1117(c).

- 157. Medline's actions are willful and deliberate and amount to exceptional circumstances, justifying an award of attorneys' fees to McAirlaids pursuant to 15 U.S.C. § 1117(a).
- 158. Unless enjoined pursuant to 15 U.S.C. § 1116, Medline's conduct will continue to cause McAirlaids irreparable harm for which there exists no adequate remedy at law.

COUNT II

(Common Law Unfair Competition/Trademark & Trade Dress Infringement)

- 159. McAirlaids repeats and specifically incorporates the allegations asserted in each of the preceding paragraphs, as if fully set forth herein.
- 160. McAirlaids is the owner of all right and title to the distinctive McAirlaids' SuperCore® mark and Trade Dress.
- 161. McAirlaids' SuperCore® mark is nonfunctional, inherently distinctive or has acquired secondary meaning and is associated in the mind of the public uniquely with McAirlaids.
- 162. McAirlaids' Trade Dress is nonfunctional, inherently distinctive or has acquired secondary meaning and is associated in the mind of the public uniquely with McAirlaids.
- 163. McAirlaids has prior and exclusive rights to use McAirlaids' SuperCore® mark and Trade Dress to identify, market, promote and sell its medical and hygienic absorbent pads, including absorbent incontinence bed pads.
- 164. Without authorization, Medline uses exact copies of McAirlaids' SuperCore® mark and Trade Dress in commerce, in connection with the sale, offering for sale, distribution, or advertising of Medline's China-made Ultrasorbs in a manner that is likely to cause confusion, or to cause mistake, or to deceive, and in a manner that is intended to cause confusion, or to cause mistake, or to deceive.

- 165. Medline has unlawfully used McAirlaids-made, Genuine Ultrasorbs advertising and McAirlaids' SuperCore® mark and Trade Dress to pass off, falsely promote and create a market for Medline's China-made Ultrasorbs and reduce sales of McAirlaids-made, Genuine Ultrasorbs.
- 166. Medline's use of the SuperCore® mark and Trade Dress in connection with the sale, offering for sale, distribution, or advertising of Medline's China-made Ultrasorbs misleads, confuses and/or deceives consumers into believing they are purchasing McAirlaids-made, Genuine Ultrasorbs that (1) are made by McAirlaids; (2) are made in the U.S.A., (3) contain McAirlaids' Patented SuperCore® Technology, (4) have proven clinical and cost-saving benefits, and (5) contain McAirlaids' Trade Dress. Instead, purchasers receive Medline's China-made Ultrasorbs that (1) are not made by McAirlaids; (2) are not made in the U.S.A., (3) do not contain McAirlaids' Patented SuperCore® Technology, (4) are not proven to have the clinical and cost-saving benefits of McAirlaids-made, Genuine Ultrasorbs, and (5) may or may not contain McAirlaids' Trade Dress.
- 167. Medline's importing, distributing, selling and marketing of its China-made Ultrasorbs in connection with McAirlaids' SuperCore® mark and Trade Dress infringes McAirlaids' exclusive rights in and to McAirlaids' SuperCore® mark and Trade Dress in violation of the common law of the Commonwealth of Virginia.
- 168. Medline's unauthorized use, adoption, appropriation and/or copying of McAirlaids' SuperCore® mark and Trade Dress deprives McAirlaids of its exclusive rights to control, and benefit from, McAirlaids' SuperCore® mark and Trade Dress.
- 169. If permitted to continue, Medline's actions will nullify McAirlaids' rights to the exclusive use of the McAirlaids' SuperCore® mark and Trade Dress, free from infringement, and will have a substantial and adverse effect on McAirlaids' existing and projected future

business of marketing and selling its absorbent pads bearing McAirlaids' SuperCore® mark and Trade Dress in violation of the common law of the Commonwealth of Virginia.

- 170. Medline's unauthorized use of McAirlaids' SuperCore® mark and Trade Dress has resulted in Medline unfairly benefiting from advertising and promotion of McAirlaids' SuperCore® mark and Trade Dress and from the resultant goodwill in McAirlaids' SuperCore® mark and Trade Dress.
- 171. By reason of and as a direct and proximate result of Medline's trademark and trade dress infringement, Medline has caused damage to McAirlaids' business, reputation and goodwill and has diverted business and sales from McAirlaids to Medline.
- 172. McAirlaids is entitled to recover its damages from Medline in an amount to be proven at trial.
- 173. Unless enjoined, Medline's conduct will cause McAirlaids irreparable harm for which there exists no adequate remedy at law.

COUNT III

(Contributory and Vicarious Infringement Under the Lanham Act & Common Law)

- 174. McAirlaids repeats and specifically incorporates the allegations asserted in each of the preceding paragraphs, as if fully set forth herein.
- 175. Medline's dealers, distributors, and resellers rely primarily, if not solely, on Medline to supply the advertising and marketing material used in connection with the sale, offering for sale, distribution, or advertising of Medline's products, including McAirlaids-made, Genuine Ultrasorbs and Medline's China-made Ultrasorbs.
- 176. Medline does not have any advertising or marketing material differentiating Medline's China-made Ultrasorbs from McAirlaids-made, Genuine Ultrasorbs, and no advertising or marketing materials disclaiming the use of McAirlaids' Patented SuperCore® Technology in Medline's China-made Ultrasorbs.

- McAirlaids' SuperCore® mark and McAirlaids' Trade Dress in connection with the sale, offering for sale, distribution, or advertising of Medline's China-made Ultrasorbs in a manner that misleads, confuses and/or deceives consumers into believing they are purchasing McAirlaids-made, Genuine Ultrasorbs that (1) are made by McAirlaids; (2) are made in the U.S.A., (3) contain McAirlaids' Patented SuperCore® Technology, (4) have proven clinical and cost-saving benefits, and (5) contain McAirlaids' Trade Dress. Instead, purchasers receive Medline's China-made Ultrasorbs that (1) are not made by McAirlaids; (2) are not made in the U.S.A., (3) do not contain McAirlaids' Patented SuperCore® Technology, (4) are not proven to have the clinical and cost-saving benefits of McAirlaids-made, Genuine Ultrasorbs, and (5) may or may not contain McAirlaids' Trade Dress.
- 178. Medline's dealers, distributors, and resellers have unlawfully used McAirlaids-made, Genuine Ultrasorbs advertising and McAirlaids' SuperCore® mark and Trade Dress to pass off, falsely promote and create a market for Medline's China-made Ultrasorbs and reduce sales of McAirlaids-made, Genuine Ultrasorbs.
- 179. Medline's dealers', distributors', and resellers' unauthorized use, adoption, appropriation and/or copying of McAirlaids' SuperCore® mark and Trade Dress deprives McAirlaids of its exclusive rights to control, and benefit from, McAirlaids' SuperCore® mark and Trade Dress.
- 180. Medline's dealers, distributors, and resellers have infringed McAirlaids'

 SuperCore® mark and Trade Dress in violation of 15 U.S.C. § 1114 and in violation of the common law of the Commonwealth of Virginia.
- 181. Medline intentionally induced and encouraged all or substantially all of its dealers, distributors, and resellers to infringe McAirlaids' SuperCore® mark and Trade Dress

when advertising and selling Medline's China-made Ultrasorbs and/or Medline continues to supply its infringing advertising, along with Medline's China-made Ultrasorbs, to its dealers, distributors and resellers whom Medline knows or has reason to know are and will continue to infringing McAirlaids SuperCore® mark and Trade Dress in connection with the sale, offering for sale, distribution, or advertising of Medline's China-made Ultrasorbs.

- 182. Indeed, Medline's Marketing Kit expressly encourages and induces dealers, distributors, and/or resellers to use Medline's marketing and advertising materials, stating: "Please encourage your staff to familiarize themselves with these [Product Reference] sheets and use them to help explain products to customers over the phone and in your store." Ex. F at 2.
- 183. Medline and its dealers, distributors, and resellers have an apparent or actual partnership, have authority to bind one another in transactions with third parties or exercise joint ownership or control over Medline's China-made Ultrasorbs and the infringing advertising of McAirlaids SuperCore® mark and Trade Dress used in connection with the sale, offering for sale, distribution, or advertising of Medline's China-made Ultrasorbs.
- 184. The Marketing Kit also supports Medline's and its dealers', distributors', and/or resellers' apparent or actual partnership and joint control over the products. *See, e.g.*, Ex. F, Module 2 at 9 ("[E]xplain when the customer can expect to receive their order. (With Medline's dropship program, customers often receive their delivery within 24 to 48 hours").
- 185. If permitted to continue, Medline's dealers', distributors', and resellers' actions will nullify McAirlaids' rights to the exclusive use of McAirlaids' SuperCore® mark and Trade Dress, free from infringement, and will have a substantial and adverse effect on McAirlaids' existing and projected future interstate business of marketing and selling its absorbent pads bearing McAirlaids' SuperCore® mark and Trade Dress in violation of 15 U.S.C. § 1114 and the common law of the Commonwealth of Virginia.

- 186. Medline's dealers', distributors', and resellers' unauthorized use of McAirlaids' SuperCore® mark and Trade Dress have resulted in Medline's dealers', distributors', and resellers' unfairly benefiting from advertising and promotion of McAirlaids' SuperCore® mark and Trade Dress and from the resultant goodwill in McAirlaids' SuperCore® mark and Trade Dress.
- 187. By reason of and as a direct and proximate result of Medline's dealers', distributors', and resellers' trademark and trade dress infringement, Medline's dealers', distributors', and resellers' have caused damage to McAirlaids' business, reputation and goodwill and have diverted business and sales from McAirlaids to Medline's dealers, distributors, and resellers.
- 188. Medline is contributorily and/or vicariously liable for the complained of unlawful infringement by its dealers, distributors, and resellers.
- 189. Under the Lanham Act, McAirlaids is entitled to an accounting and to recovery from Medline all damages, without limitation, that McAirlaids has suffered due to Medline's dealers', distributors', and resellers' infringing conduct, including Medline's dealers', distributors', and resellers' profits and damages suffered by McAirlaids in an amount to be proven at trial, the costs of the action, treble damages under 15 U.S.C. § 1117(a), treble damages and reasonable attorneys' fees for Medline's dealers', distributors', and resellers' use of the counterfeit SuperCore® mark and counterfeit Trade Dress under 15 U.S.C. § 1117(b), and/or statutory damages for use of the counterfeit mark in lieu of damages and profits under 15 U.S.C. § 1117(c).
- 190. Under the Lanham Act, Medline's and/or its dealers', distributors', and resellers' actions are willful and deliberate and amount to exceptional circumstances, justifying an award of attorneys' fees to McAirlaids pursuant to 15 U.S.C. § 1117(a).

- 191. Unless enjoined pursuant to 15 U.S.C. § 1116 and Virginia common law, Medline's dealers', distributors', and resellers' conduct will continue to cause McAirlaids irreparable harm for which there exists no adequate remedy at law.
- 192. Under Virginia common law, McAirlaids is entitled to recover its damages from Medline in an amount to be proven at trial.

(False Designation of Source & Origin Under Section 43(a) of the Lanham Act)

- 193. McAirlaids repeats and specifically incorporates the allegations asserted in each of the preceding paragraphs, as if fully set forth herein.
- 194. Medline's conduct, as alleged herein, constitutes false designation of source and origin in violation of § 43(a)(1)(A) of the Lanham Act, 15 U.S.C. §§ 1125(a)(1)(A).
- 195. Through the complained of use of McAirlaids' SuperCore® mark and Trade Dress, Medline has falsely represented that Medline's China-made Ultrasorbs originate from McAirlaids, in whole or part, and/or Medline's China-made Ultrasorbs are approved by McAirlaids or affiliated with, connected to or associated with McAirlaids and/or its SuperCore® mark, McAirlaids' Patented SuperCore® Technology and/or McAirlaids' Trade Dress.
- 196. In **Exhibit I** and elsewhere in its advertising, Medline falsely represents that the U.S.A. is the geographic source and origin of Medline's China-made Ultrasorbs.
- 197. Moreover, in **Exhibit I** and elsewhere in its advertising, Medline falsely represents that it (rather than McAirlaids) is the source and origin of SuperCore®. At the bottom of the "Incontinence Care" page, Medline states that "Aloetouch, FitRight, Protection Plus, Restore, *SuperCore*, and Ultrasorbs are registered trademarks and Capri Plus is a trademark of Medline Industries." (emphasis added). Significantly, Aloetouch®, FitRight®, Protection Plus®, Restore®, Ultrasorbs® and Capri Plus®, are all registered trademarks of Medline. By including SuperCore® among the list of Medline registered trademarks, with no attribution to

McAirlaids, Medline is misrepresenting the source and origin of SuperCore® and McAirlaids Patented SuperCore® Technology.

- 198. Similarly, **Exhibit J** contains no attribution to McAirlaids, either in connection with SuperCore® or McAirlaids' '702 Patent cited therein, and further supports Medline's false designation of source and origin for SuperCore®.
- 199. Medline's conduct is likely to cause confusion, or to cause mistake, or to deceive consumers as to the source and origin of SuperCore®, McAirlaids Trade Dress and the geographic origin of Medline's China-made Ultrasorbs which Medline is passing off as McAirlaids-made, Genuine Ultrasorbs.
- 200. By reason of and as a direct and proximate result of Medline's false designations of source and origin, Medline has caused damage to McAirlaids' business, reputation and goodwill and/or has diverted business and sales from McAirlaids to Medline. McAirlaids is entitled to recover Medline's profits, damages suffered by McAirlaids and the costs of the action.
- 201. Medline's acts of false designation of source and origin have been committed knowingly, willfully, deliberately and maliciously with the intent to cause confusion and mistake and to deceive. Accordingly, McAirlaids is entitled to a judgment of three times its damages and Medline's ill-gotten profits, together with reasonable attorneys' fees, pursuant to 15 U.S.C. § 1117.
- 202. By reason of and as a direct and proximate result of Medline's unlawful acts and practices, including those set forth herein, Medline has caused, is causing, and unless such acts and practices are enjoined by the Court, will continue to cause, immediate and irreparable harm to McAirlaids, for which there is no adequate remedy at law, and for which McAirlaids is entitled to injunctive relief.

COUNT V (False Advertising Under Section 43(a) of the Lanham Act)

- 203. McAirlaids repeats and specifically incorporates the allegations asserted in each of the preceding paragraphs, as if fully set forth herein.
- 204. As set forth herein, Medline has violated and continues to violate Section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).
- 205. The conduct of Medline and its dealers, distributors, and resellers, as described herein, constitutes false advertising. The statements and representations made by Medline and its dealers, distributors and resellers are likely to mislead, or have misled, consumers about the nature, characteristics, quality and geographic origin of Medline's China-made Ultrasorbs, and are likely to cause, or have caused, consumers to falsely believe, among other things, that Medline's China-made Ultrasorbs (1) are made by McAirlaids, (2) are made in the U.S.A., (3) contain McAirlaids' Patented SuperCore® Technology, (4) have proven clinical and cost-saving benefits, and (5) contain McAirlaids' Trade Dress, all in violation of Section 43(a) of the Lanham Act, 15 U.S.C. § 1125.
- 206. Medline and its dealers, distributors and/or resellers have engaged in a false advertising campaign to pass off Medline's China-made Ultrasorbs as McAirlaids-made, Genuine Ultrasorbs.
- 207. By reason of and as a direct and proximate result of Medline' and its dealers, distributors and/or resellers false advertising, Medline and its dealers, distributors and/or resellers have caused damage to McAirlaids' business, reputation and goodwill and/or have diverted business and sales from McAirlaids to Medline and its dealers, distributors and/or resellers. McAirlaids is entitled to recover Medline's profits, damages suffered by McAirlaids and the costs of the action.

- 208. Medline's and its dealers', distributors', and resellers' wrongful conduct are causing damage and immediate irreparable harm to McAirlaids' reputation through: (1) McAirlaids' false association with the production of cheaper, inferior products made in China; (2) McAirlaids' association with the false advertisements to purchasers; (3) McAirlaids' diminishing goodwill in its SuperCore® mark through its association with Medline's Chinamade Ultrasorbs; and (4) McAirlaids' diminishing goodwill in its '702 Patent from the patent's association with Medline's Chinamade Ultrasorbs.
- 209. Medline's and its dealers', distributors', and resellers' wrongful conduct are causing damage and immediate irreparable harm to McAirlaids' economic interest by: (1) reducing sales and demand for McAirlaids-made, Genuine Ultrasorbs; (2) reducing the goodwill and economic value of McAirlaids' SuperCore® mark, McAirlaids' '702 Patent and Trade Dress; (3) intermingling McAirlaids-made, Genuine Ultrasorbs with Medline's China-made Ultrasorbs in the marketplace and creating a false sense of equivalency.
- 210. Medline's and its dealers', distributors', and resellers' acts of false advertising have been committed knowingly, willfully, deliberately and maliciously with the intent to cause confusion and mistake and to deceive.
- 211. Accordingly, McAirlaids is entitled to a judgment of three times its damages and Medline's ill-gotten profits, together with reasonable attorneys' fees, pursuant to 15 U.S.C. § 1117.
- 212. By reason of and as a direct and proximate result of Medline's unlawful acts and practices, including those set forth herein, Medline has caused, is causing, and unless such acts and practices are enjoined by the Court, will continue to cause, immediate and irreparable harm to McAirlaids, for which there is no adequate remedy at law, and for which McAirlaids is entitled to injunctive relief.

COUNT VI

(Contributory and Vicarious False Advertising and False Designation of Source and Origin Under § 43(a) of the Lanham Act)

- 213. McAirlaids repeats and specifically incorporates the allegations asserted in each of the preceding paragraphs, as if fully set forth herein.
- 214. As set forth herein, Medline is contributorily and vicariously liable for its dealers', distributors' and resellers' violations of Section 43(a)(1)(B) of the Lanham Act, 15 U.S.C. § 1125(a)(1)(B).
- 215. By reason of and as a direct and proximate result of Medline's and its dealers', distributors' and/or resellers' false advertising, Medline and its dealers, distributors and/or resellers have caused damage to McAirlaids' business, reputation and goodwill and/or have diverted business and sales from McAirlaids to Medline and its dealers, distributors and/or resellers. McAirlaids is entitled to recover from Medline, Medline's dealers', distributors' and resellers' profits, damages suffered by McAirlaids and the costs of the action.
- 216. Medline's and its dealers', distributors', and resellers' acts of false advertising and false designation of source and origin have been committed knowingly, willfully, deliberately and maliciously with the intent to cause confusion and mistake and to deceive.
- 217. Accordingly, McAirlaids is entitled to a judgment of three times its damages and Medline's dealers', distributors' and resellers' ill-gotten profits, together with reasonable attorneys' fees, pursuant to 15 U.S.C. § 1117.
- 218. By reason of and as a direct and proximate result of Medline's dealers', distributors' and resellers' unlawful acts and practices set forth herein, Medline's dealers', distributors' and resellers' have caused, are causing, and unless such acts and practices are enjoined by the Court, will continue to cause, immediate and irreparable harm to McAirlaids, for

which there is no adequate remedy at law, and for which McAirlaids is entitled to injunctive relief.

COUNT VII (False Advertising Under Virginia Code §§ 18.2-216, 59.1-68.3)

- 219. McAirlaids repeats and specifically incorporates the allegations asserted in each of the preceding paragraphs, as if fully set forth herein.
- 220. The actions of Medline described herein including but not limited to the use of false and deceptive and misleading claims about Medline's China-made Ultrasorbs to solicit customers through online marketing materials, direct customer communications, and other means constitutes false and misleading advertising in violation of Virginia Code §§ 18.2-216 and 59.1-68.3, and McAirlaids has suffered and is continuing to suffer losses to its business reputation and goodwill as a result thereof.
- 221. Medline's actions, as alleged herein, were intended to wrongfully divert sales and business from McAirlaids to Medline.
- 222. Medline's advertisements, as alleged herein, contained false assertions, representations, and statements of fact which are untrue, deceptive or misleading.
- 223. Medline has made and distributed these customer solicitations through websites and other means in Virginia.
- 224. McAirlaids has no adequate remedy at law and is suffering irreparable harm which will continue unless enjoined.
- 225. Medline's conduct has caused damage to McAirlaids' business, reputation and goodwill, and McAirlaids seeks recovery of the same in an amount to be determined at trial.

 McAirlaids is entitled to recover attorneys' fees under Virginia Code § 59.1-68.3.

WHEREFORE, McAirlaids respectfully requests that the Court:

- Award Judgment in favor of McAirlaids and against Medline on all counts of the Complaint;
- Award McAirlaids its actual and compensatory damages, without limitation, sustained due to Medline's unlawful and infringing conduct in violation of McAirlaids legal and equitable rights;
- 3. Order Medline to provide an accounting, impose a constructive trust, and award McAirlaids restitution, disgorgement of all profits derived from Medline's and its dealers', distributors' and resellers' unlawful and infringing conduct and/or other equitable remedies in an amount to be proven at trial;
- 4. Award McAirlaids full and complete relief, including, without limitation, its costs and reasonable attorney's fees, for Medline's violations of federal and common law trademark and trade dress infringement, unfair competition, false designation of source and origin, and false advertising;
 - Award McAirlaids treble damages;
 - Award McAirlaids any available punitive damages;
- 7. Permanently enjoin Medline a from all unlawful and infringing acts that violate McAirlaids' legal and equitable rights;
- 8. Temporarily, preliminarily and/or permanently restrain and enjoin Medline, its officers, directors, employees, agents, and representatives, and any and all persons in active concert or participation with any of them, including Medline's dealers, distributors and resellers, from:

- (a) Continuing to falsely market or advertise Medline's China-made Ultrasorbs as:
 - (i) made by McAirlaids;
 - (ii) made in the U.S.A.;
 - (iii) containing McAirlaids' Patented SuperCore® Technology;
 - (iv) having proven clinical and cost-saving benefits; and
 - (v) containing McAirlaids' Trade Dress.
- (b) Continuing to pass off Medline's China-made Ultrasorbs as McAîrlaids-made, Genuine Ultrasorbs with McAirlaids Patented SuperCore® Technology and/or manufactured pursuant to McAirlaids' '702 Patented process;
- (c) Continuing to infringe McAirlaids' SuperCore® trademark in connection with the marketing, advertising, selling and offering for sale of Medline's China-made Ultrasorbs; and
- (d) Continuing to source, sell or offer for sale Medline's China-made Ultrasorbs until such time as Medline has successfully demonstrated to the Court that Medline has:
 - (i) fully complied with Paragraphs 8(a)-(c) above; and
- (ii) fully performed all of the following corrective actions to eliminate and prevent purchaser and marketplace confusion and false impressions of equivalency between Medline's China-made Ultrasorbs and McAirlaids-made, Genuine Ultrasorbs:
- (1) Issuing, emailing and mailing a formal written public retraction to all of its Ultrasorbs dealers, distributors, resellers, and purchasers attaching a copy of the Preliminary Injunction Order and advising them that: (i) Medline has sourced, sold, and offered for sale Medline's China-made Ultrasorbs; (ii) Medline's China-made Ultrasorbs are not

McAirlaids-made, Genuine Ultrasorbs; (iii) Medline's China-made Ultrasorbs are not manufactured, in whole or part, by McAirlaids; (iv) unlike McAirlaids-made, Genuine Ultrasorbs, Medline's China-made Ultrasorbs are not made in the U.S.A.; (v) Medline's Chinamade Ultrasorbs do not contain McAirlaids' Patented SuperCore® Technology; (vi) Medline's China-made Ultrasorbs were not the subject of or tested in the hospital study by Shannon, R. and LaJoie, J. entitled Economic Impact of Ultrasorbs AP Absorbent Pads in Prevention of Hospital-Acquired Pressure Ulcers. Global Health Economic Projects, LLC and New York Methodist Hospital, Brooklyn NY. March 2009 ("Hospital Study") and have not been clinically shown to help maintain skin integrity as part of an overall pressure ulcer prevention program or provide the cost-savings benefits identified in the Hospital Study; (vii) Medline's China-made Ultrasorbs do not contain McAirlaids' Trade Dress; and (viii) McAirlaids-made, Genuine Ultrasorbs with McAirlaids' Patented SuperCore® Technology were the subject of and tested in the Hospital Study and were clinically shown to help maintain skin integrity as part of an overall pressure ulcer prevention program as stated in the Hospital Study and were shown to provide the costsavings benefits identified in the Hospital Study (collectively, the "Formal Public Retraction").

(2) Issuing a press release containing its Formal Public Retraction, and prominently and continuously displaying its Formal Public Retraction on its website www.medline.com and in its marketing materials, on the websites and in the marketing materials of its Ultrasorbs dealers, distributors and resellers, and in all other materials in connection with the advertising, selling or offering for sale of any Ultrasorbs.

- 9. Grant such other and further relief as the Court deems just and equitable; and
- Order a trial by jury on all appropriate issues.

11.

Dated: April 29, 2015 Respectfully submitted,

MCAIRLAID'S VLIESSTOFFE GMBH, and MCAIRLAIDS, INC.

By /s/ Joshua F. P. Long
Of Counsel

Joshua F. P. Long (VSB #65684)
J. Benjamin Rottenborn (VSB #84796)
Joshua R. Treece (VSB #79149)
WOODS ROGERS PLC
10 S. Jefferson Street, Suite 1400
P.O. Box 14125
Roanoke, Virginia 24011
Telephone: (540) 983-7625
Facsimile: (540) 983-7711
jlong@woodsrogers.com

Counsel for Plaintiffs McAirlaid's Vliesstoffe GmbH and McAirlaids, Inc.

CERTIFICATE OF SERVICE

I certify that on this 29th day of April, 2015, a copy of the foregoing was filed with Court and served via e-mail on all counsel of record in the related case McAirlaids v. Medline, 7:15-cv-6-MFU (W.D. Va. 2014).

Bv: /s	/ Joshua F. P. Long	
--------	---------------------	--